Hellenic J Cardiol
November 2024
Objective: Treating iron deficiency (ID) with ferric carboxymaltose (FCM) in patients with heart failure with reduced ejection fraction (HFrEF) enhances morbidity, quality of life (QoL), and exercise capacity.
Methods: In the presented single-center, prospective follow-up study, symptomatic patients with HFrEF with ID and CIEDs scheduled for IV FCM were followed up for 12-months. Arrhythmic activity was evaluated from CIEDs and non-invasive markers from Holter recordings before and after FCM.
Aims: To systematically appraise and summarize the available evidence from published randomized controlled trials considering the effect of nebivolol on blood pressure in patients with hypertension.
Methods: Literature search was performed through Medline (via PubMed), Cochrane Library and Scopus until December 15, 2023. Double-independent study selection, data extraction and quality assessment were performed.
Hormones (Athens)
October 2024